EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by thebiological subtype of the tumor. Her2-positive breast cancer is characterized by an aggressi...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2021-05-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1760 |
| _version_ | 1797875780923949056 |
|---|---|
| author | O. I. Kit L. Yu. Vladimirova E. A. Kalabanova A. E. Storozhakova S. N. Kabanov T. A. Snezhko I. S. Mitashok Ya. V. Svetitskaya N. Yu. Samaneva I. S. Kornilova Yu. V. Przhedetskiy V. V. Pozdnyakova N. A. Abramova I. L. Popova N. M. Tikhanovskaya A. A. Lyanova K. A. Novoselova L. A. Ryadinskaya |
| author_facet | O. I. Kit L. Yu. Vladimirova E. A. Kalabanova A. E. Storozhakova S. N. Kabanov T. A. Snezhko I. S. Mitashok Ya. V. Svetitskaya N. Yu. Samaneva I. S. Kornilova Yu. V. Przhedetskiy V. V. Pozdnyakova N. A. Abramova I. L. Popova N. M. Tikhanovskaya A. A. Lyanova K. A. Novoselova L. A. Ryadinskaya |
| author_sort | O. I. Kit |
| collection | DOAJ |
| description | Background. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by thebiological subtype of the tumor. Her2-positive breast cancer is characterized by an aggressive course and unfavorable prognosis. The use of pertuzumab, a recombinant humanized monoclonal antibody to the human epidermal growth factor receptor 2, significantly improved immediate and long-term treatment outcomes. The aim of the study was to evaluate treatment outcomes in patients with Her2-positive molecular subtype of breast cancer receiving chemotherapy combined with a dual anti-Her2 blockade, and to assess the intensityand incidence of side effects. Material and methods. Between 2015 and 2018, 37 patients with Her2-positive breast cancer received chemotherapy combined with a dual anti-HER2 blockade (docetaxel 75 mg/m2 i/v on day 1 + trastuzumab 6 mg/kg (loading dose 8 mg/kg) i/v on day 1 + pertuzumab 420 mg (loading dose 840 mg) i/v on day 1 once every 3 weeks). The mean age of the patients was 45.6 ± 11.6 years. Results. Neoadjuvant pertuzumab in combination with trastuzumab and docetaxel resulted in pathological complete response in 12 % of patients and pathological partial response in 36 % of patients. Among patients who received the above neoadjuvant therapy regimen, disease progression was observed in 4 % of patients. The most common side effects were weakness and fatigue (5.4 % of cases) and grade I–II leukopenia (5.4 %).Conclusion. The study demonstrated the efficacy of antitumor therapy with pertuzumab in combination with trastuzumab and docetaxel as well as the absence of severe side effects associated with this treatment regimen in patients with Her2-positive breast cancer. |
| first_indexed | 2024-04-10T01:51:56Z |
| format | Article |
| id | doaj.art-37520b7ab3864c81a9d042b834977f6f |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:51:56Z |
| publishDate | 2021-05-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-37520b7ab3864c81a9d042b834977f6f2023-03-13T09:05:54ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682021-05-01202859210.21294/1814-4861-2021-20-2-85-92848EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCERO. I. Kit0L. Yu. Vladimirova1E. A. Kalabanova2A. E. Storozhakova3S. N. Kabanov4T. A. Snezhko5I. S. Mitashok6Ya. V. Svetitskaya7N. Yu. Samaneva8I. S. Kornilova9Yu. V. Przhedetskiy10V. V. Pozdnyakova11N. A. Abramova12I. L. Popova13N. M. Tikhanovskaya14A. A. Lyanova15K. A. Novoselova16L. A. Ryadinskaya17ФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииФГБУ «Национальный медицинский исследовательский центр онкологии» Министерства здравоохранения Российской ФедерацииBackground. Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by thebiological subtype of the tumor. Her2-positive breast cancer is characterized by an aggressive course and unfavorable prognosis. The use of pertuzumab, a recombinant humanized monoclonal antibody to the human epidermal growth factor receptor 2, significantly improved immediate and long-term treatment outcomes. The aim of the study was to evaluate treatment outcomes in patients with Her2-positive molecular subtype of breast cancer receiving chemotherapy combined with a dual anti-Her2 blockade, and to assess the intensityand incidence of side effects. Material and methods. Between 2015 and 2018, 37 patients with Her2-positive breast cancer received chemotherapy combined with a dual anti-HER2 blockade (docetaxel 75 mg/m2 i/v on day 1 + trastuzumab 6 mg/kg (loading dose 8 mg/kg) i/v on day 1 + pertuzumab 420 mg (loading dose 840 mg) i/v on day 1 once every 3 weeks). The mean age of the patients was 45.6 ± 11.6 years. Results. Neoadjuvant pertuzumab in combination with trastuzumab and docetaxel resulted in pathological complete response in 12 % of patients and pathological partial response in 36 % of patients. Among patients who received the above neoadjuvant therapy regimen, disease progression was observed in 4 % of patients. The most common side effects were weakness and fatigue (5.4 % of cases) and grade I–II leukopenia (5.4 %).Conclusion. The study demonstrated the efficacy of antitumor therapy with pertuzumab in combination with trastuzumab and docetaxel as well as the absence of severe side effects associated with this treatment regimen in patients with Her2-positive breast cancer.https://www.siboncoj.ru/jour/article/view/1760рак молочной железыher2-положительный подтиппертузумабпрогноз |
| spellingShingle | O. I. Kit L. Yu. Vladimirova E. A. Kalabanova A. E. Storozhakova S. N. Kabanov T. A. Snezhko I. S. Mitashok Ya. V. Svetitskaya N. Yu. Samaneva I. S. Kornilova Yu. V. Przhedetskiy V. V. Pozdnyakova N. A. Abramova I. L. Popova N. M. Tikhanovskaya A. A. Lyanova K. A. Novoselova L. A. Ryadinskaya EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER Сибирский онкологический журнал рак молочной железы her2-положительный подтип пертузумаб прогноз |
| title | EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER |
| title_full | EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER |
| title_fullStr | EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER |
| title_full_unstemmed | EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER |
| title_short | EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER |
| title_sort | experience of using pertuzumab in anticancer therapy for her2 positive breast cancer |
| topic | рак молочной железы her2-положительный подтип пертузумаб прогноз |
| url | https://www.siboncoj.ru/jour/article/view/1760 |
| work_keys_str_mv | AT oikit experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT lyuvladimirova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT eakalabanova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT aestorozhakova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT snkabanov experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT tasnezhko experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT ismitashok experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT yavsvetitskaya experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT nyusamaneva experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT iskornilova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT yuvprzhedetskiy experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT vvpozdnyakova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT naabramova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT ilpopova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT nmtikhanovskaya experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT aalyanova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT kanovoselova experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer AT laryadinskaya experienceofusingpertuzumabinanticancertherapyforher2positivebreastcancer |